Braintree, Buyers Settle Generic MiraLax Suit For $17M

Law360, Los Angeles (January 20, 2012, 7:16 PM EST) -- Drug buyer plaintiffs in a putative antitrust class action accusing Braintree Laboratories Inc. of initiating baseless patent litigation to block a generic version of the laxative MiraLax asked a Delaware federal judge Friday to approve a $17.25 million settlement of direct purchaser claims.

Rochester Drug Cooperative Inc., Louisiana Wholesale Drug Co. and Meijer Inc. — which bought MiraLax directly from Braintree at what they claim was an inflated cost — filed a motion Friday asking U.S. District Judge Sue L. Robinson to certify a class of...
To view the full article, register now.